Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
198.70B
Market cap198.70B
Price-Earnings ratio
10.88
Price-Earnings ratio10.88
Dividend yield
2.76%
Dividend yield2.76%
Average volume
9.51M
Average volume9.51M
High today
$45.09
High today$45.09
Low today
$44.22
Low today$44.22
Open price
$44.60
Open price$44.60
Volume
3.52M
Volume3.52M
52 Week high
$64.16
52 Week high$64.16
52 Week low
$35.12
52 Week low$35.12

NVO News

Nasdaq 49m
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

Key Points AbbVie is successfully transitioning its revenue base toward newer immunology drugs to offset the loss of patent protection for Humira. Novo Nordis...

AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
TipRanks 2h
Novo Nordisk’s Heart Failure Trial Setback: What NVO Investors Should Watch Next

Novo Nordisk (NVO) announced an update on their ongoing clinical study. The study “Effects of Ziltivekimab Versus Placebo on Morbidity and Mortality in Patient...

TipRanks 2h
Novo Nordisk’s CagriSema Trial Targets Painful Diabetic Nerve Damage

Novo Nordisk (NVO) announced an update on their ongoing clinical study. The study, officially titled “Efficacy and Safety of co Administered Cagrilintide and S...

More NVO News

Nasdaq 8h
Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There.

Key Points Viking Therapeutics is studying its weight-loss drug candidate in phase 3 trials. Today Eli Lilly and Novo Nordisk dominate the market, but high de...

Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There.
TipRanks 1d
Novo Nordisk Advances Oral Semaglutide Trial in Obesity: What Investors Should Watch

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Novo Nordisk’s new Phase 3 trial, “Efficacy and Safety of Once Daily Oral Semaglutide i...

TipRanks 1d
Novo Nordisk Advances DKK 15 Billion Share Buyback, Holding 1% of Capital in Treasury Stock

An announcement from Novo Nordisk ( (NVO) ) is now available. Novo Nordisk has continued executing its previously announced share repurchase programme, which f...

Simply Wall St 2d
Novo Nordisk (CPSE:NOVO B) Stock Looks Cheap Even As Caution Lingers - simplywall.st

...

Novo Nordisk (CPSE:NOVO B) Stock Looks Cheap Even As Caution Lingers - simplywall.st
Nasdaq 2d
Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore?

Key Points Novo Nordisk was first to market with a GLP-1 weight-loss drug, but lost the lead to Eli Lilly. Novo Nordisk has been working hard to regain lost m...

Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore?
Seeking Alpha 2d
Novo Nordisk faces fresh setback as it halts two heart drug trials

Novo Nordisk (NVO) has halted two late-stage trials of its experimental heart drug ziltivekimab, adding to the drugmaker’s recent pipeline setbacks. The Danish...

Novo Nordisk faces fresh setback as it halts two heart drug trials
TipRanks 3d
Novo Nordisk halts two trials testing ziltivekimab, Bloomberg reports

Novo Nordisk (NVO) has halted two trials testing if ziltivekimab, its experimental heart disease medicine, would help patients with heart failure, Ashleigh Furl...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.